These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 16465362)

  • 21. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
    Gajewski TF; Fallarino F; Ashikari A; Sherman M
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):895s-901s. PubMed ID: 11300489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2.
    Bjoern J; Brimnes MK; Andersen MH; Thor Straten P; Svane IM
    Scand J Immunol; 2011 Mar; 73(3):222-33. PubMed ID: 21204893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
    Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
    J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
    Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
    Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.
    Whiteside TL; Zhao Y; Tsukishiro T; Elder EM; Gooding W; Baar J
    Clin Cancer Res; 2003 Feb; 9(2):641-9. PubMed ID: 12576430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
    Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
    Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
    Linette GP; Zhang D; Hodi FS; Jonasch EP; Longerich S; Stowell CP; Webb IJ; Daley H; Soiffer RJ; Cheung AM; Eapen SG; Fee SV; Rubin KM; Sober AJ; Haluska FG
    Clin Cancer Res; 2005 Nov; 11(21):7692-9. PubMed ID: 16278389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
    Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
    Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
    Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
    Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
    Lienard D; Avril MF; Le Gal FA; Baumgaertner P; Vermeulen W; Blom A; Geldhof C; Rimoldi D; Pagliusi S; Romero P; Dietrich PY; Corvaia N; Speiser DE
    J Immunother; 2009 Oct; 32(8):875-83. PubMed ID: 19752746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
    Ridolfi L; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Brolli C; Selva M; Scarpi E; Valmorri L; Nicoletti SV; Guidoboni M; Riccobon A; Ridolfi R
    Melanoma Res; 2011 Dec; 21(6):524-9. PubMed ID: 21909041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
    Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
    Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.